Aarhus University Seal / Aarhus Universitets segl

Disease activity patterns, mortality and colorectal cancer risk in microscopic colitis: a Danish nationwide cohort study, 2001 to 2016

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • Petra Weimers, North Zealand University Hospital
  • ,
  • Dorit Vedel Ankersen, North Zealand University Hospital
  • ,
  • Søren Lophaven, Omicron Aps
  • ,
  • Ole Kristian Bonderup
  • ,
  • Andreas Münch, Department of Infectious Diseases, Linköping University Hospital, Linköping, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • ,
  • Ellen Christine Leth Løkkegaard, North Zealand University Hospital
  • ,
  • Pia Munkholm, North Zealand University Hospital
  • ,
  • Johan Burisch, North Zealand University Hospital

BACKGROUND AND AIMS: The disease course of microscopic colitis (MC), encompassing collagenous colitis (CC) and lymphocytic colitis (LC), is not well known. In a Danish nationwide cohort, we evaluated the disease activity patterns as well as the risk of colorectal cancer (CRC) and mortality based on disease severity.

METHODS: All incident MC patients (n=14,302) with a recorded diagnosis of CC (n=8,437) or LC (n=5,865) in the Danish Pathology Register entered between 2001 and 2016 were matched to 10 reference individuals (n=142,481). Incident cases of CRC after the index date were captured from the Danish Cancer Registry. Mortality data were ascertained from The Danish Registry of Causes of Death and information about treatment were obtained from The Danish National Prescription Registry. The risk of CRC and mortality analyses were investigated by Cox regression and Kaplan-Meier estimates.

RESULTS: We identified a self-limiting or transient disease course in 70.6% of LC patients and in 59.9% of CC patients, p<0.001. Less than 5% of MC patients experienced a budesonide-refractory disease course and were treated with immunomodulators or biological treatment. A total of 2,926 (20.5%) MC patients and 24,632 (17.3%) reference individuals died during the study period. MC patients with a severe disease had a relative risk (RR) of mortality of 1.41 (95% CI: 1.32-1.50) compared to reference individuals. Only 90 MC patients were diagnosed with CRC during follow-up, corresponding to a RR of 0.48 (95% CI: 0.39-0.60).

CONCLUSIONS: A majority of MC patients experience an indolent disease course with a lower risk of developing CRC compared to the background population.

Original languageEnglish
Article numberjjaa207
JournalJournal of Crohn's & colitis
Pages (from-to)594-602
Number of pages9
Publication statusPublished - Apr 2021

See relations at Aarhus University Citationformats

ID: 207892714